Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
about
Cellular senescence and tumor suppressor gene p16p53 acetylation is crucial for its transcription-independent proapoptotic functionsDNA methylation and microRNAs in cancerDimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugA novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancerPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersA phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitorsTreatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells.Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathwayMelding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Administration of a Histone Deacetylase Inhibitor into the Basolateral Amygdala Enhances Memory Consolidation, Delays Extinction, and Increases Hippocampal BDNF Levels.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Histone deacetylase inhibitors: discovery and development as anticancer agents.Histone deacetylase (HDAC) 1 controls the expression of beta defensin 1 in human lung epithelial cells.Molecular modeling study on tunnel behavior in different histone deacetylase isoforms.The GOD of hematopoietic stem cells: a clonal diversity model of the stem cell compartment.HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsHDAC inhibition and graft versus host diseaseHistone deacetylase regulation of immune gene expression in tumor cells.Targeting PML-RARα and Oncogenic Signaling Pathways by Chinese Herbal Mixture Tien-Hsien Liquid in Acute Promyelocytic Leukemia NB4 CellsThe synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.FHL2 regulates hematopoietic stem cell functions under stress conditionsEpigenetics in breast and prostate cancerEvaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brainEfficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.On the inhibition of histone deacetylase 8Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.Romidepsin in the treatment of cutaneous T-cell lymphoma.Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR SignalingPhase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.Efficacy of vorinostat in a murine model of polycythemia veraBortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and BimTreatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.
P2860
Q24629853-809044D6-8C35-4F7D-A5BF-AB734D4EB82CQ24657909-A7C80396-B561-4B52-A605-945580CE6B9FQ26852479-77AB5950-66C1-43C0-BD56-3401537AADFEQ28282479-9EF7C4CA-6E97-48D2-A61D-9D0DC5797AF7Q28475503-CCCB5BEC-04EC-4D34-B1ED-377F6FFD9EAAQ28535006-9AD1F783-B550-4FAD-82BF-A89219E573E0Q33381378-10D04F0B-9C00-4090-97B1-CD157670446EQ33407501-2FAEC23D-BAF0-427C-BE10-4EB64530DF96Q33409828-352CEE1F-6825-4BF1-B147-BC1E22477806Q33416734-E1355794-DF75-49E8-AFD1-0A8E35C7CD43Q33655696-41ED0BAD-F2A1-43D5-9281-FF19B2DB7B72Q33744417-31C04783-967B-4E1F-8825-08D91D04EC56Q33827019-32390F36-A5B3-443A-A6D8-A8737C7CB4DFQ33831971-0BFCC308-42AD-47CA-9E32-3FB2B68CEF85Q33843223-FC0674B4-8B40-451B-95E5-E2431D32D25BQ34399444-FE0F967C-B1FF-4D3B-ADDA-F0445E7F62F1Q34414452-334DFF61-D3C9-4E09-B486-CD064374C270Q34470150-E6B3A3BE-4F4D-4F74-949F-13BC8A382844Q34490868-57A928BF-3F18-49BE-A662-F61F3938A883Q34499630-C374F8A9-4486-4652-B7D7-683F65C13DEAQ34624692-CB09AAE4-D2D1-45CC-9FBE-497DECBDA113Q34988013-D3202215-8025-4100-98B7-C9DDB6E601DCQ34994576-117E1798-9801-40CA-A6F8-5100FE4269E6Q35016985-2CEAA72B-AC5F-4A50-9174-577510376ADAQ35092304-35F0177B-AEEC-4DBE-96E7-291535C51281Q35109736-2347A070-C9C3-4605-B0FD-86C445254974Q35133494-61E4F39C-5A74-466F-844D-AB73DFD46377Q35137904-97477A11-863E-4D4B-B75C-69DA7CB57E89Q35190483-1489BA15-BF08-4F2F-A4DB-D1197C382D7BQ35198599-16457F53-3884-42E8-A1C9-067161A5D7B8Q35572018-2712D6A8-6E9B-4DE8-8546-4DAB1E00EC65Q35633424-E8426F5C-D2FC-4C26-9883-1B72B1AAB4E5Q35669576-037A267B-CF12-49FB-AF04-7D8A0C0FE1C4Q35683831-D2C49681-D40D-4524-BFBB-79EF2AAAC5A1Q35749913-A430119E-8B2B-408F-B6CC-D84273B1FF3EQ35750919-FCE06E20-99C6-4B42-86B8-25FE9367991AQ35835233-54C1967B-417A-43F6-BCCF-6F0AE8F65AF5Q35909673-C6B90E4C-3094-43DA-B640-D2ECFD32BEAFQ35982670-E2B72166-9FDE-4CB9-AB25-6928B7F72C16Q36001895-E81A93A7-4978-4A84-9B23-A022038D5889
P2860
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@ast
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@en
type
label
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@ast
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@en
prefLabel
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@ast
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@en
P356
P1476
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
@en
P2093
Kapil N Bhalla
P304
P356
10.1200/JCO.2005.16.600
P407
P577
2005-05-16T00:00:00Z